From Sequencing to Treatment: Operational Challenges in Translating Precision Oncology Into Clinical Practice

Precision oncology has fundamentally reshaped cancer treatment by enabling therapies to be matched to the molecular biology of individual tumors. Advances in next-generation sequencing (NGS) technologies, expanding biomarker discovery, and an increasing number of targeted therapies have made comprehensive molecular testing an integral component of modern oncology practice. Realizing the full clinical impact of these technologies requires understanding not only the biological alterations detected but also the diagnostic workflows through which genomic information is generated and interpreted. NGS-based assays differ substantially in their design, particularly in terms of sequencing breadth, depth, and the chemistry involved in library prep. These technical characteristics influence the types of genomic alterations that can be detected, the analytical sensitivity of testing, and the clinical confidence with which results can be interpreted. Preanalytic variables-including tissue adequacy, nucleic acid quality, and specimen handling-are equally critical, as they determine whether molecular testing can be successfully performed and whether the resulting data accurately reflect tumor biology. Once genomic results are available, clinicians must interpret a diverse range of molecular alterations, including single-nucleotide variants, copy number changes, structural rearrangements, and composite genomic signatures. Structured reporting practices, multidisciplinary interpretation through molecular tumor boards, and evidence-based actionability frameworks help translate these findings into clinically meaningful treatment decisions. Ultimately, maximizing the impact of precision oncology requires coordinated integration across molecular diagnostics, clinical interpretation, and health care delivery systems. By understanding each step of this pathway-from specimen acquisition to therapeutic decision making-clinicians can more effectively translate genomic insights into improved patient outcomes.